|Source||Humanized (from mouse)|
|Main uses||Reversal of dabigatran|
|Side effects||Headache, nausea, constipation|
|Typical dose||5 gram|
|Chemical and physical data|
|Molar mass||47782.71 g·mol−1|
Idarucizumab, sold under the brand name Praxbind, is a medication used to reverse the effects of dabigatran. Specifically it is used if severe bleeding or urgent surgery is required. It is given by injection into a vein.
Common side effects include headache, nausea, and constipation. Severe side effects may include blood clots and allergic reactions. It is a monoclonal antibody that works by binding to and inactivating dabigatran.
Idarucizumab was approved for medical use in the United States and Europe in 2015. In the United Kingdom it costs the NHS about £2,400 for a dose as of 2021. This amount in the United States costs about 4,500 USD.
Dabigatran can be started again once 24 hours has passed from this medication being given.
Society and culture
- "Praxbind- idarucizumab injection". DailyMed. 1 December 2019. Retrieved 19 August 2020.
- "Praxbind EPAR". European Medicines Agency (EMA). Retrieved 16 October 2020.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 131. ISBN 978-0857114105.
- "Praxbind Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 25 November 2021.
- World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1): 90–91. hdl:10665/331151.
- World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3): 544. hdl:10665/331020.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab, American Medical Association.